Swiss drug development company Relief Therapeutics Holdings SA (Relief Therapeutics)(SWX:RLF) said on 23 September 2020 that along with its US partner NeuroRx, it has asked the US Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, Reuters news agency reported on Wednesday.
Citing a 51-person study, Relief Therapeutics said in a statement: "Patients treated with RLF-100 demonstrated a three-fold advantage in survival, recovery from respiratory failure and other parameters indicative of meaningful clinical improvement."
The company added that the request, if granted, would make the drug, previously used against conditions including erectile dysfunction, available to those in intensive care who have exhausted all approved treatments.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid